Javier Cid | Senior Research Scientist, Real-World Evidence
Evidera, part of the PPD clinical research business of Thermo Fisher Scientific

Javier Cid, Senior Research Scientist, Real-World Evidence, Evidera, part of the PPD clinical research business of Thermo Fisher Scientific

Javier Cid, MD, DrPH, MBA, MSc, is a Senior Research Scientist in the RWE group at Evidera, part of the PPD clinical research business of Thermo Fisher Scientific, in Barcelona, Spain.  Dr. Cid is a healthcare professional with more than 20 years of experience, 11 of which were spent working for two major pharmaceutical companies, mainly in the areas of pharmacoepidemiology and drug safety. He has contributed to several therapeutic risk management plans and related interactions with health authorities in European, American, and Asian countries. Dr. Cid has experience in the planning, implementation, and analysis of several drug and disease registries and databases, as well as in the development and implementation of signal detection for pharmacovigilance. His research projects rely mainly on data from secondary data sources, and some of them also include the collection of primary data.

Appearances:



Day 2 - Wednesday 30th October @ 13:00

Unlocking the Power of Real-World Data (RWD) and Real-World Evidence (RWE) in Vaccine Development: A Comprehensive Approach to RWE Across the Lifecycle

Regulators and payors are increasingly integrating real-world evidence (RWE) of safety, effectiveness, and value to inform their decision-making.

Discover how RWE, generated using real-world data (RWD), can provide valuable insights from early in development and throughout the vaccine lifecycle.

Join us as we:

  • Explore the diverse types of RWE that can effectively support vaccine development
  • Provide insights into planning for the collection of RWD throughout vaccine development
  • Discuss opportunities to leverage RWD within clinical trials
  • Share examples of uses of RWE from early stage through post-marketing
By considering RWD and RWE early in the development process, manufacturers can optimize integrated evidence generation strategies to expedite vaccine development, approval, and market access.

Key takeaways from the session will include:

-          Understanding how RWD can be used to produce RWE in support of the clinical development and lifecycle of vaccines

-          Recognizing how RWE complements evidence from clinical trials

Identifying challenges and opportunities in planning for RWE generation during vaccine development

last published: 03/Oct/24 13:35 GMT

back to speakers